Vasopressin Market Report 2026

Vasopressin Market Overview

• Vasopressin market size has reached to $1.57 billion in 2025 • Expected to grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: Rising Diabetes Rates Fuel Growth in Vasopressin Market • Market Trend: New Ready-To-Use Concentrated Formulation Enhances Dosing Precision And Safety In Critical-Care Settings • North America was the largest region in 2025.

What Is Covered Under Vasopressin Market?

Vasopressin, also known as antidiuretic hormone (ADH), is a peptide hormone produced by the hypothalamus and released by the posterior pituitary gland into the bloodstream. It plays a crucial role in regulating the body's water and blood pressure, maintaining water balance, regulating blood pressure, and responding to stress. The main product types of vasopressin are intravenous injection, intramuscular injection, subcutaneous injection. Vasopressin administered via intravenous injection delivers the hormone directly into the bloodstream. These are used in various applications such as anti-diuretic hormone deficiency, vasodilatory shock, gastrointestinal bleeding, ventricular tachycardia and fibrillation and also by various end-users such as hospitals, clinics, and others.

What Is The Vasopressin Market Growth Forecast?

The vasopressin market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing incidence of septic shock, rising ICU admissions, advancements in critical care protocols, growing awareness of hormonal disorders, expansion of emergency medicine infrastructure. Major trends in the forecast period include rising use in critical care and shock management, growing demand in sepsis and intensive care units, increased adoption in hormonal deficiency treatment, expansion of injectable hormone therapies, higher focus on emergency care applications.

Global Vasopressin Market Segmentation

1) By Product Type: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection 2) By Application: Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia And Fibrillation 3) By End-User: Hospitals, Clinics, Other End Users Subsegments: 1) By Intravenous Injection: Standard Iv Vasopressin Injection, High-Dose Iv Vasopressin Injection, Iv Vasopressin For Sepsis And Shock Treatment, Iv Vasopressin For Post-Operative Care 2) By Intramuscular Injection: Standard Im Vasopressin Injection, Intramuscular Vasopressin For Hormonal Imbalance, Vasopressin Injection For Acute Hemorrhage Control 3) By Subcutaneous Injection: Subcutaneous Vasopressin For Diabetes Insipidus

What Are The Drivers Of The Vasopressin Market?

The growing prevalence of diabetes is expected to propel the growth of the vasopressin market going forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood, resulting from the body's inability to produce or effectively use insulin. The prevalence of diabetes is due to increasing obesity rates, stress and mental health, and genetic factors. Vasopressin is crucial in managing central diabetes insipidus, as it helps restore average water balance and alleviate the symptoms of excessive urination and thirst. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the growing prevalence of diabetes is driving the vasopressin industry. The growing geriatric population is expected to propel the growth of the vasopressin market moving forward. The geriatric population refers to older adults, typically aged 65 years and above, who often require specialized healthcare and support due to age-related physiological changes. The growing geriatric population is primarily due to increasing life expectancy, which allows people to live longer, and declining birth rates, which reduce the proportion of younger individuals in the population. Vasopressin supports the geriatric population by helping maintain blood pressure stability and improving kidney function, thereby addressing age-related cardiovascular and renal vulnerabilities. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population is driving the growth of the vasopressin industry.

Key Players In The Global Vasopressin Market

Major companies operating in the vasopressin market are Pfizer Inc., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, Amphastar Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals Inc., Eagle Pharmaceuticals Inc., Par Pharmaceutical Holdings Inc., Fresenius Kabi, Nordic Pharma Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Inc., Amneal Pharmaceuticals Inc., Bachem Holding AG, BCN Peptides SA, Laboratorio ELEA S.A.C.I.F. y A., Hainan Zhonghe Pharmaceutical Co. Ltd., Cumberland Pharmaceuticals Inc., AMOMED Pharma GmbH

Global Vasopressin Market Trends and Insights

Major companies operating in the vasopressin market are developing innovative solutions such as higher-concentration ready-to-use vasopressin formulations to improve dosing precision, reduce preparation time, and enhance safety in critical-care settings. Higher-concentration ready-to-use vasopressin refers to a premixed intravenous formulation containing a higher unit-per-mL ratio that eliminates the need for bedside dilution, supports faster initiation, and minimizes dosing errors during management of vasodilatory shock. For instance, in March 2024, Baxter Healthcare Corporation, a US-based pharmaceutical and medical device company, received FDA approval for Vasopressin in 0.9% Sodium Chloride Injection, 50 units/50 mL (1 unit/mL), a concentrated ready-to-use vasopressin formulation featuring a fixed 1-unit/mL strength that reduces the need for frequent bag changes, a premixed single-dose presentation that eliminates compounding steps, and compatibility with standard infusion systems to streamline administration in emergency and intensive-care settings.

Regional Insights

North America was the largest region in the vasopressin market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vasopressin Market?

The vasopressin market consists of sales of arginine vasopressin (AVP), vasopressin receptor, oral tablets, sublingual tablets, nasal sprays, and oil-repository material. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vasopressin Market Report 2026?

The vasopressin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vasopressin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.